Gregory Fraser
Stock Analyst at Truist Securities
(3.31)
# 956
Out of 4,786 analysts
35
Total ratings
51.85%
Success rate
15.68%
Average return
Main Sectors:
Stocks Rated by Gregory Fraser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $220 → $230 | $124.15 | +85.26% | 1 | Mar 6, 2025 | |
| ANIP ANI Pharmaceuticals | Maintains: Hold | $60 → $62 | $66.95 | -7.39% | 8 | Oct 22, 2024 | |
| BHC Bausch Health Companies | Maintains: Hold | $8 → $7 | $6.47 | +8.19% | 2 | Jul 25, 2024 | |
| XAIR Beyond Air | Maintains: Buy | $10 → $8 | $0.27 | +2,835.78% | 6 | Apr 30, 2024 | |
| BTMD biote | Maintains: Buy | $10 → $9 | $3.33 | +170.27% | 2 | Jan 18, 2024 | |
| AMRX Amneal Pharmaceuticals | Maintains: Buy | $6 → $7 | $8.38 | -16.47% | 4 | Nov 8, 2023 | |
| CORT Corcept Therapeutics | Maintains: Hold | $26 → $29 | $114.22 | -74.61% | 5 | Aug 3, 2023 | |
| NVCR NovoCure | Reiterates: Buy | $95 | $17.82 | +433.11% | 3 | Jun 6, 2023 | |
| EOLS Evolus | Maintains: Buy | $14 → $18 | $12.03 | +49.63% | 2 | May 26, 2023 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $45 → $40 | $15.64 | +155.75% | 2 | May 26, 2023 |
Jazz Pharmaceuticals
Mar 6, 2025
Maintains: Buy
Price Target: $220 → $230
Current: $124.15
Upside: +85.26%
ANI Pharmaceuticals
Oct 22, 2024
Maintains: Hold
Price Target: $60 → $62
Current: $66.95
Upside: -7.39%
Bausch Health Companies
Jul 25, 2024
Maintains: Hold
Price Target: $8 → $7
Current: $6.47
Upside: +8.19%
Beyond Air
Apr 30, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $0.27
Upside: +2,835.78%
biote
Jan 18, 2024
Maintains: Buy
Price Target: $10 → $9
Current: $3.33
Upside: +170.27%
Amneal Pharmaceuticals
Nov 8, 2023
Maintains: Buy
Price Target: $6 → $7
Current: $8.38
Upside: -16.47%
Corcept Therapeutics
Aug 3, 2023
Maintains: Hold
Price Target: $26 → $29
Current: $114.22
Upside: -74.61%
NovoCure
Jun 6, 2023
Reiterates: Buy
Price Target: $95
Current: $17.82
Upside: +433.11%
Evolus
May 26, 2023
Maintains: Buy
Price Target: $14 → $18
Current: $12.03
Upside: +49.63%
Arcutis Biotherapeutics
May 26, 2023
Maintains: Buy
Price Target: $45 → $40
Current: $15.64
Upside: +155.75%